Life Sciences
The partners are employing AI to identify undiagnosed and undertreated patients, support clinical trials and advance precision therapies.
Developed by Cancer Institute NSW, the multi-data-trained tool aims to educate people over 40 about their cancer risks.
During a fireside chat with Scripta Insights’ CEO, Cuban discussed TrumpRx and unveiled new MCCPDC innovations, including mobile drug-making pods and the Cost Plus Wellness network.
The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.
The funds will be used to bolster AI and computational physics-based model development for numerous modalities.
Early results show 70% accuracy of AI-assisted detection of unexplained male infertility using Asian IVF data.
The company helps match patients to relevant clinical trials and engages in recruitment for biopharma partners.
The company recently presented clinical data at the European Society for Medical Oncology Congress for an investigational drug that displayed anti-tumor activity and a good safety profile.
The model also calculates biological ageing and survival patterns to support personalized health risk management.
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.